Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar

The aim of this seminar was to offer general discussion on emerging clinical and scientific concepts in pulmonary fibrosis including:

advances in autoimmune and idiopathic fibrosis with regard to both pathogenesis and treatment
diagnostic and prognostic evaluation, monitoring, and current and novel treatment approaches in idiopathic and autoimmune disease
recent important clinical statements and studies
laboratory science with s focus on the pathogenesis of fibrosis

Download all media

Welcome by ERS President N. Siafakas (Heraklion, Greece)
HRCT in the diagnosis of diffuse lung disease - overlap issues D. Hansell (London, United Kingdom)
Histological diagnosis in diffuse lung disease - how pathologists think A. Nicholson (London, United Kingdom)
The clinican's dilemma - when is biopsy required? V. Poletti (Forli, Italy)
Prognostic evaluation of idiopathic interstitial pneumonia: emerging data A. Wells (London, United Kingdom)
Prognostic evaluation in connective tissue disease: a pragmatic algorithm V. Cottin (Lyon, France)
Bronchoalvolar Lavage (BAL) in diffuse lung disease: Pros & Cons C. Robalo Cordeiro (Coimbra, Portugal)
The diagnosis of IPF: recommendations & rationale L. Richeldi (Modena, Italy); P. Spagnolo (Modena, Italy)
The management of IPF D. Bouros (Alexandroupolis, Greece)
Unresolved controversies: the unwritten pages A. Wells (London, United Kingdom)
Pulmonary hypertension in Pulmonary Fibrosis: detection & treatment Z. Daniil (Larissa, Greece)
Smoking and pulmonary fibrosis K. Antoniou (Heraklion, Greece)
Non invasive biomarkers in the diagnostic and prognostic evaluation of Pulmonary Fibrosis S. Loukides (Athens, Greece)
IPF and lung cancer: what are the links? V. Poletti (Forli, Italy)
Pulmonary fibrosis: ongoing trials and future treatment V. Cottin (Lyon, France)
Is TGFb a central mediator in the development of pulmonary fibrosis? G. Jenkins (Nottingham, United Kingdom), A. Tatler (Nottingham, United Kingdom)
Phospholipid homeostasis and IPF pathogenesis V. Aidinis (Vari, Greece)
Oxidant/Antioxidant imbalance: a potential contributor to pulmonary fibrosis J. Behr (Munich, Germany)
Epithelial mesenchymal transition M. Keane (Dublin, Ireland)
The current classification of the idiopathic interstitial pneumonias: has it advanced pathogenetic understanding O. Eickelberg (Munich, Germany)
A plethora of pathways, a medley of mediators: how do we tease out pathogenesis G. Laurent (London, United Kingdom)
Genetics of pulmonary fibrosis M. Petrek (Olomouc, Czech Republic)
CON - Animal models: are they still useful? T. Maher (St Albans, United Kingdom)